Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
NeurAxis, Inc. (NRXS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
4Distinct source URLs
6High confidence
0.756Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NeurAxis, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CRAIG-HALLUM-CAPITAL-GROUP-LLC
CRAIG-HALLUM-CAPITAL-GROUP-LLC
92%
As previously disclosed, on August 29, 2025, the Company entered into an At The Market Offering Agreement (the “Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”) under which the Com…
Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXS graph: Reciprocal relationship from ORAN…
alid and scientifically supported approach to the treatment of neurological conditions, and accordingly, we expect for competition in the non-implanted space to grow in the future. While many compani…
DATE-TITLE-APPLICATION-STATUS-LICENSING-STATUS-C
DATE-TITLE-APPLICATION-STATUS-LICENSING-STATUS-C
62%
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
tial monetary awards to study participants or patients; ● product recalls, withdrawals or labeling, marketing or promotional restrictions; ● loss of revenues; ● exhaustion of any available insurance …
INNOVATIVE-HEALTH-SOLUTIONS-INC
INNOVATIVE-HEALTH-SOLUTIONS-INC
62%
l statements are an integral part of these statements. F- 5 Neuraxis, Inc. Statements of Cash Flows 2025 2024 For the Years Ended December 31, 2025 2024 Cash Flows from Operating Activities Net loss …
JP-NEURAXIS-INC
JP-NEURAXIS-INC
62%
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla…
QSR-NEURAXIS-INC
QSR-NEURAXIS-INC
62%
s review often takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or clarification of information already provided, an…
US-NEURAXIS-INC
US-NEURAXIS-INC
62%
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla…
NeurAxis, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NRXS-DEBT-11374
Warrants outstanding: 0.01
90%
xbrl warrant detail from xbrl 2025-12-31.
NRXS-DEBT-11375
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
NRXS-DEBT
Debt stack $271,068
90%
Market cache reports total debt of $271,068.
NeurAxis, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NeurAxis, Inc..
NeurAxis, Inc. Ownership
Holder
Name
Confidence
Evidence
NRXS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 26 tracked holders.
